首页 > 最新文献

Urology Practice最新文献

英文 中文
Editorial Commentary. 编辑评论。
IF 1.7 Q4 UROLOGY & NEPHROLOGY Pub Date : 2026-02-11 DOI: 10.1097/UPJ.0000000000000976
David T Tzou
{"title":"Editorial Commentary.","authors":"David T Tzou","doi":"10.1097/UPJ.0000000000000976","DOIUrl":"https://doi.org/10.1097/UPJ.0000000000000976","url":null,"abstract":"","PeriodicalId":45220,"journal":{"name":"Urology Practice","volume":" ","pages":"101097UPJ0000000000000976"},"PeriodicalIF":1.7,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146150914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adjuvant PD-1 Inhibitors After Radical Surgery For High-Risk Muscle-Invasive Urothelial Carcinoma: A Systematic Review And Meta-Analysis Of Phase III Trials. 高危肌浸润性尿路上皮癌根治性手术后PD-1辅助抑制剂:III期试验的系统回顾和荟萃分析
IF 1.7 Q4 UROLOGY & NEPHROLOGY Pub Date : 2026-02-10 DOI: 10.1097/UPJ.0000000000000984
Wala Ben Kridis, Afef Khanfir

Background: Patients with high-risk muscle-invasive urothelial carcinoma remain at substantial risk of disease recurrence. Randomized phase III trials have evaluated adjuvant programmed death 1 (PD-1) inhibitors in this setting, but the magnitude and consistency of benefit across patient subgroups remain incompletely defined.

Methods: We performed a systematic review and meta-analysis of randomized phase III trials comparing adjuvant PD-1 inhibitors with placebo or observation in patients with resected high-risk muscle-invasive urothelial carcinoma. Hazard ratios (HRs) for disease-free survival (DFS) and overall survival (OS), as well as risk ratios (RRs) for adverse events, were pooled using random-effects models. Prespecified subgroup analyses were conducted according to PD-L1 expression and prior receipt of cisplatin-based neoadjuvant chemotherapy.

Results: Two phase III trials encompassing patients treated with adjuvant nivolumab or pembrolizumab were included. Adjuvant PD-1 inhibitor therapy significantly improved DFS compared with control (pooled HR <1), with consistent benefit observed across PD-L1-defined subgroups and regardless of prior neoadjuvant cisplatin use. A favorable trend toward improved OS was observed, although survival data remain immature. Treatment was associated with a higher incidence of grade 3 or higher and immune-related adverse events compared with placebo or observation.

Conclusions: Among patients with resected high-risk muscle-invasive urothelial carcinoma, adjuvant PD-1 inhibitor therapy significantly improves disease-free survival with an acceptable safety profile. However, due to the limited number of studies and short follow-up periods, these findings should be considered preliminary, and longer follow-up is required to confirm any potential overall survival benefit.

背景:高危肌肉侵袭性尿路上皮癌患者仍有很大的疾病复发风险。随机III期试验已经评估了这种情况下的辅助程序性死亡1 (PD-1)抑制剂,但在患者亚组中获益的幅度和一致性仍然不完全确定。方法:我们对随机III期试验进行了系统回顾和荟萃分析,比较了PD-1辅助抑制剂与安慰剂或观察在切除的高危肌肉侵袭性尿路上皮癌患者中的应用。使用随机效应模型汇总无病生存期(DFS)和总生存期(OS)的风险比(hr)以及不良事件的风险比(rr)。根据PD-L1表达和先前接受以顺铂为基础的新辅助化疗进行预先指定的亚组分析。结果:纳入了两项III期试验,包括接受辅助治疗的患者纳武单抗或派姆单抗。与对照组相比,PD-1辅助抑制剂治疗显著改善了DFS (pooled HR)。结论:在切除的高风险肌肉侵袭性尿路上皮癌患者中,PD-1辅助抑制剂治疗显著提高了无病生存,且安全性可接受。然而,由于研究数量有限,随访时间短,这些发现应被视为初步的,需要更长的随访时间来证实任何潜在的总体生存益处。
{"title":"Adjuvant PD-1 Inhibitors After Radical Surgery For High-Risk Muscle-Invasive Urothelial Carcinoma: A Systematic Review And Meta-Analysis Of Phase III Trials.","authors":"Wala Ben Kridis, Afef Khanfir","doi":"10.1097/UPJ.0000000000000984","DOIUrl":"https://doi.org/10.1097/UPJ.0000000000000984","url":null,"abstract":"<p><strong>Background: </strong>Patients with high-risk muscle-invasive urothelial carcinoma remain at substantial risk of disease recurrence. Randomized phase III trials have evaluated adjuvant programmed death 1 (PD-1) inhibitors in this setting, but the magnitude and consistency of benefit across patient subgroups remain incompletely defined.</p><p><strong>Methods: </strong>We performed a systematic review and meta-analysis of randomized phase III trials comparing adjuvant PD-1 inhibitors with placebo or observation in patients with resected high-risk muscle-invasive urothelial carcinoma. Hazard ratios (HRs) for disease-free survival (DFS) and overall survival (OS), as well as risk ratios (RRs) for adverse events, were pooled using random-effects models. Prespecified subgroup analyses were conducted according to PD-L1 expression and prior receipt of cisplatin-based neoadjuvant chemotherapy.</p><p><strong>Results: </strong>Two phase III trials encompassing patients treated with adjuvant nivolumab or pembrolizumab were included. Adjuvant PD-1 inhibitor therapy significantly improved DFS compared with control (pooled HR <1), with consistent benefit observed across PD-L1-defined subgroups and regardless of prior neoadjuvant cisplatin use. A favorable trend toward improved OS was observed, although survival data remain immature. Treatment was associated with a higher incidence of grade 3 or higher and immune-related adverse events compared with placebo or observation.</p><p><strong>Conclusions: </strong>Among patients with resected high-risk muscle-invasive urothelial carcinoma, adjuvant PD-1 inhibitor therapy significantly improves disease-free survival with an acceptable safety profile. However, due to the limited number of studies and short follow-up periods, these findings should be considered preliminary, and longer follow-up is required to confirm any potential overall survival benefit.</p>","PeriodicalId":45220,"journal":{"name":"Urology Practice","volume":" ","pages":"101097UPJ0000000000000984"},"PeriodicalIF":1.7,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146150986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
External validation of a post-operative renal function predictive model following partial nephrectomy. 部分肾切除术后肾功能预测模型的外部验证。
IF 1.7 Q4 UROLOGY & NEPHROLOGY Pub Date : 2026-02-10 DOI: 10.1097/UPJ.0000000000000980
Emily Nham, Luke T Lavallée, Ranjeeta Mallick, Dean A Fergusson, Christopher Morash, Antonio Finelli, Frédéric Pouliot, Jonathan Izawa, Ricardo Rendon, Ilias Cagiannos, Rodney H Breau

Introduction: A predictive model from the Veterans Affairs National Health System estimates glomerular filtration rate (eGFR) 1-year following partial nephrectomy (PN). The model demonstrated a coefficient of determination (R2) of 0.66, with 82% of patients having a post-operative eGFR within 30% of the predicted GFR (P30). The purpose of this study is to assess its performance in patients enrolled in the renal hypothermia trial.

Methods: The model was externally validated using data from the renal hypothermia randomized clinical trial where GFR was measured using 99mTc-DTPA plasma clearance pre-PN and 1-year post-PN. Model performance was evaluated using R2, calibration slope, calibration plot, and precision (P10: within 10%; P20; within 20%; and P30 within 30%).

Results: The trial cohort included 175 patients with pre- and post-PN complete data. The R2 was 0.67. The model was reasonably precise with 73 patients within 10% of predicted GFR (P10=41.7%), 129 within 20% of predicted GFR (P20=73.7%) and 156 within 30% of predicted GFR (P30=89.1%). The calibration slope was 1.04, with good calibration across a wide range of baseline renal function. Limitations include modest sample size, predominantly Caucasian patients, and restriction to open PN, limiting generalizability.

Conclusions: A recently developed model to predict post-operative GFR performed well when applied to clinical trial patients that had GFR measured using 99mTc-DTPA plasma clearance. This model can be utilized as a component of informed decision-making when counseling patients on expected outcomes following partial nephrectomy.

来自退伍军人事务国家卫生系统的预测模型估计部分肾切除术(PN)后1年的肾小球滤过率(eGFR)。该模型的决定系数(R2)为0.66,82%的患者术后eGFR在预测GFR的30%以内(P30)。本研究的目的是评估其在肾低温试验患者中的表现。方法:使用肾低温随机临床试验的数据对模型进行外部验证,该试验使用99mTc-DTPA血浆清除率在pn前和pn后1年测量GFR。采用R2、校准斜率、校准图和精度对模型性能进行评价(P10:在10%以内;P20;在20%以内;P30在30%以内)。结果:试验队列包括175例pn术前和术后数据完整的患者。R2为0.67。该模型较为精确,73例患者GFR在预测的10%以内(P10=41.7%), 129例患者GFR在预测的20%以内(P20=73.7%), 156例患者GFR在预测的30%以内(P30=89.1%)。校准斜率为1.04,在大范围的基线肾功能范围内具有良好的校准。局限性包括样本量适中,主要是高加索患者,限制开放PN,限制了推广。结论:最近开发的预测术后GFR的模型在应用于使用99mTc-DTPA血浆清除率测量GFR的临床试验患者时表现良好。该模型可作为知情决策的组成部分,当咨询患者的预期结果后,部分肾切除术。
{"title":"External validation of a post-operative renal function predictive model following partial nephrectomy.","authors":"Emily Nham, Luke T Lavallée, Ranjeeta Mallick, Dean A Fergusson, Christopher Morash, Antonio Finelli, Frédéric Pouliot, Jonathan Izawa, Ricardo Rendon, Ilias Cagiannos, Rodney H Breau","doi":"10.1097/UPJ.0000000000000980","DOIUrl":"https://doi.org/10.1097/UPJ.0000000000000980","url":null,"abstract":"<p><strong>Introduction: </strong>A predictive model from the Veterans Affairs National Health System estimates glomerular filtration rate (eGFR) 1-year following partial nephrectomy (PN). The model demonstrated a coefficient of determination (R<sup>2</sup>) of 0.66, with 82% of patients having a post-operative eGFR within 30% of the predicted GFR (P30). The purpose of this study is to assess its performance in patients enrolled in the renal hypothermia trial.</p><p><strong>Methods: </strong>The model was externally validated using data from the renal hypothermia randomized clinical trial where GFR was measured using <sup>99m</sup>Tc-DTPA plasma clearance pre-PN and 1-year post-PN. Model performance was evaluated using R<sup>2</sup>, calibration slope, calibration plot, and precision (P10: within 10%; P20; within 20%; and P30 within 30%).</p><p><strong>Results: </strong>The trial cohort included 175 patients with pre- and post-PN complete data. The R<sup>2</sup> was 0.67. The model was reasonably precise with 73 patients within 10% of predicted GFR (P10=41.7%), 129 within 20% of predicted GFR (P20=73.7%) and 156 within 30% of predicted GFR (P30=89.1%). The calibration slope was 1.04, with good calibration across a wide range of baseline renal function. Limitations include modest sample size, predominantly Caucasian patients, and restriction to open PN, limiting generalizability.</p><p><strong>Conclusions: </strong>A recently developed model to predict post-operative GFR performed well when applied to clinical trial patients that had GFR measured using <sup>99m</sup>Tc-DTPA plasma clearance. This model can be utilized as a component of informed decision-making when counseling patients on expected outcomes following partial nephrectomy.</p>","PeriodicalId":45220,"journal":{"name":"Urology Practice","volume":" ","pages":"101097UPJ0000000000000980"},"PeriodicalIF":1.7,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146150906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identifying Patient-Perpetrated Racial Discrimination among the Urologic Workforce: A cross-sectional cohort study. 识别泌尿科工作人员中患者犯下的种族歧视:一项横断面队列研究。
IF 1.7 Q4 UROLOGY & NEPHROLOGY Pub Date : 2026-01-30 DOI: 10.1097/UPJ.0000000000000979
Helen A Gambrah, Catherine S Nam, Kathleen T Lee, Elizabeth M Viglianti
{"title":"Identifying Patient-Perpetrated Racial Discrimination among the Urologic Workforce: A cross-sectional cohort study.","authors":"Helen A Gambrah, Catherine S Nam, Kathleen T Lee, Elizabeth M Viglianti","doi":"10.1097/UPJ.0000000000000979","DOIUrl":"https://doi.org/10.1097/UPJ.0000000000000979","url":null,"abstract":"","PeriodicalId":45220,"journal":{"name":"Urology Practice","volume":" ","pages":"101097UPJ0000000000000979"},"PeriodicalIF":1.7,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146087569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial Commentary. 编辑评论。
IF 1.7 Q4 UROLOGY & NEPHROLOGY Pub Date : 2026-01-26 DOI: 10.1097/UPJ.0000000000000965
Reza Ghavamian
{"title":"Editorial Commentary.","authors":"Reza Ghavamian","doi":"10.1097/UPJ.0000000000000965","DOIUrl":"10.1097/UPJ.0000000000000965","url":null,"abstract":"","PeriodicalId":45220,"journal":{"name":"Urology Practice","volume":" ","pages":"101097UPJ0000000000000965"},"PeriodicalIF":1.7,"publicationDate":"2026-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146031094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial Commentary. 编辑评论。
IF 1.7 Q4 UROLOGY & NEPHROLOGY Pub Date : 2026-01-26 DOI: 10.1097/UPJ.0000000000000964
Richard J Boxer
{"title":"Editorial Commentary.","authors":"Richard J Boxer","doi":"10.1097/UPJ.0000000000000964","DOIUrl":"10.1097/UPJ.0000000000000964","url":null,"abstract":"","PeriodicalId":45220,"journal":{"name":"Urology Practice","volume":" ","pages":"101097UPJ0000000000000964"},"PeriodicalIF":1.7,"publicationDate":"2026-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146031136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-World Utility of Cxbladder Triage for Patients with Microhematuria: A Matched Cohort Study. 膀胱分诊对微血尿患者的实际应用:一项匹配队列研究。
IF 1.7 Q4 UROLOGY & NEPHROLOGY Pub Date : 2026-01-20 DOI: 10.1097/UPJ.0000000000000972
Christopher P Filson, Jeffrey M Slezak, Tiffany Q Luong, Tamer Aboushwareb, Ronald K Loo

Purpose: To evaluate real-world utility of adding Cxbladder Triage test to microhematuria diagnostic workflow in an integrated healthcare system.

Materials and methods: We conducted a retrospective matched cohort study of microhematuria patients tested with Cxbladder Triage, a urine-based biomarker of mRNA targets and clinical factors to assess urothelial cancer risk. We matched untested controls based on age, encounter date, and hematuria risk index score. The cohort was stratified by Cxbladder Triage result; low probability (<4.00, cystoscopy could be deferred) vs physician-directed protocol (≥4.00, cystoscopy recommended). We evaluated the use of cystoscopy, CT urograms, and new diagnoses of bladder cancer.

Results: We matched 3,353 patients tested with Cxbladder Triage with 3,353 controls according to American Urological Association (AUA) risk (15.7% AUA low risk for cases and controls, p=0.362). Among 3,353 tested patients, 2,670 (79.6%) had low probability of cancer and were less likely to undergo cystoscopy (3.8% vs 46.5% controls, p<0.001). Tested patients with elevated risk for cancer (n=683) were more likely to undergo cystoscopy (73.4% vs 45.7% controls, p<0.001). Similar patterns were seen for CT urogram (7.5% vs 11.7% low probability; 19.5% vs 13.3% physician-directed protocol, both p<0.001). Cancer detection was similar between both groups (0.3% tested vs 0.6% controls, p=0.105) and between tested patients with elevated risk vs untested controls (1.5% physician-directed protocol vs 0.6% controls, p=0.107).

Conclusions: Cxbladder Triage testing decreases burden of cystoscopy and CT urogram use among microhematuria patients. This test maintains similar cancer detection overall and among microhematuria patients at greater risk for underlying malignancy.

目的:评估在综合医疗保健系统中将膀胱分诊试验加入到微量血尿诊断工作流程中的实际效用。材料和方法:我们进行了一项回顾性匹配队列研究,对微血尿患者进行了膀胱分诊测试,这是一种基于尿液的mRNA靶点和临床因素的生物标志物,用于评估尿路上皮癌风险。我们根据年龄、相遇日期和血尿风险指数评分对未测试的对照组进行匹配。根据膀胱分诊结果对队列进行分层;结果:我们将3353例接受膀胱分诊的患者与3353例根据美国泌尿协会(AUA)风险进行匹配的对照组(15.7%的病例和对照组的AUA风险低,p=0.362)。在3353例接受检测的患者中,2670例(79.6%)患癌症的可能性较低,且较少接受膀胱镜检查(3.8% vs 46.5%对照)。结论:膀胱分诊检查减轻了微量血尿患者膀胱镜检查和CT尿图使用的负担。该检测在总体上和潜在恶性肿瘤风险较高的微血尿患者中保持相似的癌症检测。
{"title":"Real-World Utility of Cxbladder Triage for Patients with Microhematuria: A Matched Cohort Study.","authors":"Christopher P Filson, Jeffrey M Slezak, Tiffany Q Luong, Tamer Aboushwareb, Ronald K Loo","doi":"10.1097/UPJ.0000000000000972","DOIUrl":"https://doi.org/10.1097/UPJ.0000000000000972","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate real-world utility of adding Cxbladder Triage test to microhematuria diagnostic workflow in an integrated healthcare system.</p><p><strong>Materials and methods: </strong>We conducted a retrospective matched cohort study of microhematuria patients tested with Cxbladder Triage, a urine-based biomarker of mRNA targets and clinical factors to assess urothelial cancer risk. We matched untested controls based on age, encounter date, and hematuria risk index score. The cohort was stratified by Cxbladder Triage result; low probability (<4.00, cystoscopy could be deferred) vs physician-directed protocol (≥4.00, cystoscopy recommended). We evaluated the use of cystoscopy, CT urograms, and new diagnoses of bladder cancer.</p><p><strong>Results: </strong>We matched 3,353 patients tested with Cxbladder Triage with 3,353 controls according to American Urological Association (AUA) risk (15.7% AUA low risk for cases and controls, p=0.362). Among 3,353 tested patients, 2,670 (79.6%) had low probability of cancer and were less likely to undergo cystoscopy (3.8% vs 46.5% controls, p<0.001). Tested patients with elevated risk for cancer (n=683) were more likely to undergo cystoscopy (73.4% vs 45.7% controls, p<0.001). Similar patterns were seen for CT urogram (7.5% vs 11.7% low probability; 19.5% vs 13.3% physician-directed protocol, both p<0.001). Cancer detection was similar between both groups (0.3% tested vs 0.6% controls, p=0.105) and between tested patients with elevated risk vs untested controls (1.5% physician-directed protocol vs 0.6% controls, p=0.107).</p><p><strong>Conclusions: </strong>Cxbladder Triage testing decreases burden of cystoscopy and CT urogram use among microhematuria patients. This test maintains similar cancer detection overall and among microhematuria patients at greater risk for underlying malignancy.</p>","PeriodicalId":45220,"journal":{"name":"Urology Practice","volume":" ","pages":"101097UPJ0000000000000972"},"PeriodicalIF":1.7,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146012246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does the VA Risk Analysis Index Overestimate Frailty in Patients with Localized Prostate Cancer? VA风险分析指数是否高估了局限性前列腺癌患者的脆弱性?
IF 1.7 Q4 UROLOGY & NEPHROLOGY Pub Date : 2026-01-20 DOI: 10.1097/UPJ.0000000000000973
Pranay Manda, Siddharth Marthi, Ernest Morton, Mihir Patel, Dattatraya Patil, Taylor Goodstein, Akanksha Mehta, Shreyas Joshi, Martin Sanda, Mohammad Hajiha

Introduction and objectives: The Veterans Affairs (VA) Health System recently implemented the Risk Analysis Index (RAI) to assess frailty prior to surgery. Elevated RAI scores trigger a "surgical pause" and geriatric consultation to reduce short-term morbidity. However, any cancer diagnosis, including localized prostate cancer (PCa), increases RAI, potentially overstating frailty in otherwise healthy patients. We hypothesized that low- or intermediate-risk PCa does not correlate with 30-day morbidity and mortality predicted by RAI.

Methods: We retrospectively reviewed patients with low- or intermediate-risk PCa who underwent radical prostatectomy at a single institution over five years. RAI-A (administrative) scores were calculated with and without including PCa. Thirty-day postoperative complications and mortality were compared to rates predicted by RAI-A using data from the original VASQIP study.

Results: Among 130 patients (median age 61), 53.4% had favorable intermediate-risk, 41.2% unfavorable intermediate-risk, and 5.3% low-risk PCa. Mean RAI-A excluding PCa was 8.58; including PCa it was 24.95. Corresponding VASQIP-predicted complication rates were 4.6% (2.5% grade IV-V) and 11.2% (5.6% grade IV-V). In our cohort, six patients (4.6%) experienced complications, none grade IV-V.

Conclusions: Including localized PCa in RAI-A calculations overestimates frailty and predicted morbidity. Excluding the PCa diagnosis may better reflect surgical risk in low- or intermediate-risk patients, preventing unnecessary delays in treatment.

简介和目标:退伍军人事务(VA)卫生系统最近实施了风险分析指数(RAI)来评估手术前的虚弱程度。升高的RAI评分触发“手术暂停”和老年会诊以减少短期发病率。然而,任何癌症诊断,包括局限性前列腺癌(PCa),都会增加RAI,潜在地夸大了其他健康患者的虚弱。我们假设低或中危PCa与RAI预测的30天发病率和死亡率无关。方法:我们回顾性分析了在同一机构接受根治性前列腺切除术的低或中危前列腺癌患者,时间超过5年。RAI-A(行政)评分计算包括和不包括PCa。使用原始VASQIP研究的数据,将术后30天的并发症和死亡率与raa预测的比率进行比较。结果:在130例患者中(中位年龄61岁),53.4%为有利中危PCa, 41.2%为不利中危PCa, 5.3%为低危PCa。排除PCa的平均RAI-A为8.58;包括PCa,为24.95。相应的vasqip预测并发症发生率为4.6% (IV-V级为2.5%)和11.2% (IV-V级为5.6%)。在我们的队列中,6名患者(4.6%)出现了并发症,没有IV-V级。结论:在raa计算中包括局部PCa高估了虚弱和预测的发病率。排除前列腺癌诊断可以更好地反映低或中危患者的手术风险,防止不必要的治疗延误。
{"title":"Does the VA Risk Analysis Index Overestimate Frailty in Patients with Localized Prostate Cancer?","authors":"Pranay Manda, Siddharth Marthi, Ernest Morton, Mihir Patel, Dattatraya Patil, Taylor Goodstein, Akanksha Mehta, Shreyas Joshi, Martin Sanda, Mohammad Hajiha","doi":"10.1097/UPJ.0000000000000973","DOIUrl":"https://doi.org/10.1097/UPJ.0000000000000973","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>The Veterans Affairs (VA) Health System recently implemented the Risk Analysis Index (RAI) to assess frailty prior to surgery. Elevated RAI scores trigger a \"surgical pause\" and geriatric consultation to reduce short-term morbidity. However, any cancer diagnosis, including localized prostate cancer (PCa), increases RAI, potentially overstating frailty in otherwise healthy patients. We hypothesized that low- or intermediate-risk PCa does not correlate with 30-day morbidity and mortality predicted by RAI.</p><p><strong>Methods: </strong>We retrospectively reviewed patients with low- or intermediate-risk PCa who underwent radical prostatectomy at a single institution over five years. RAI-A (administrative) scores were calculated with and without including PCa. Thirty-day postoperative complications and mortality were compared to rates predicted by RAI-A using data from the original VASQIP study.</p><p><strong>Results: </strong>Among 130 patients (median age 61), 53.4% had favorable intermediate-risk, 41.2% unfavorable intermediate-risk, and 5.3% low-risk PCa. Mean RAI-A excluding PCa was 8.58; including PCa it was 24.95. Corresponding VASQIP-predicted complication rates were 4.6% (2.5% grade IV-V) and 11.2% (5.6% grade IV-V). In our cohort, six patients (4.6%) experienced complications, none grade IV-V.</p><p><strong>Conclusions: </strong>Including localized PCa in RAI-A calculations overestimates frailty and predicted morbidity. Excluding the PCa diagnosis may better reflect surgical risk in low- or intermediate-risk patients, preventing unnecessary delays in treatment.</p>","PeriodicalId":45220,"journal":{"name":"Urology Practice","volume":" ","pages":"101097UPJ0000000000000973"},"PeriodicalIF":1.7,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146012222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utility of 18F-Flotufolastat PET/CT Imaging in High-Risk Prostate Cancer in a Real-World Setting. 18f -氟福司他PET/CT成像在真实世界高风险前列腺癌中的应用
IF 1.7 Q4 UROLOGY & NEPHROLOGY Pub Date : 2026-01-12 DOI: 10.1097/UPJ.0000000000000971
Zachariah Taylor, Kayla Meyer, Nachum Stollman, Cheryl Zinar, Laurence Belkoff, Ilia Zeltser

Introduction: This investigator-initiated, prospective low-intervention phase 3 study evaluated the clinical utility of PSMA PET/CT imaging with 18F-flotufolastat (formerly 18F-rhPSMA-7.3) in men with newly diagnosed high-risk prostate cancer and negative conventional imaging. The primary endpoint was the rate of clinical upstaging and its effect on subsequent management.

Methods: A total of 113 treatment-naïve men meeting NCCN high-risk criteria were enrolled; 110 underwent PSMA PET/CT with 18F-flotufolastat. Prior to imaging, all patients had negative conventional staging, as determined by bone scan and CT or MRI. Imaging was performed 50-70 minutes post-injection of 8 mCi ± 20% 18F-flotufolastat. Results were interpreted by board-certified nuclear medicine physicians trained in PSMA imaging.

Results: 18F-flotufolastat identified extraprostatic disease in 36 of 110 patients (32.7%). Among these, 15 of 36 (41.7%) had isolated regional lymph node (N1) involvement, while 21 of 36 (58.3%) demonstrated distant metastatic (M1) disease. Of the patients who were upstaged, 34 of 36 patients (94.4%) had a change in their treatment plan. The most common treatment intensification included the addition of an androgen receptor inhibitor and expanded radiotherapy fields (50.0%). Further, 34.3% received upfront chemotherapy alongside an androgen receptor inhibitor and radiation. A minority (8.6%) proceeded with radical prostatectomy as a first step of a multimodality approach.

Conclusion: PSMA PET/CT with 18F-flotufolastat led to clinical upstaging in nearly one-third of men with high-risk prostate cancer and negative conventional imaging, resulting in significant treatment change in most patients. These findings support the integration of PSMA-targeted imaging into initial staging pathways for men with high-risk prostate cancer.

本研究由研究者发起,前瞻性低干预的3期研究评估了18F-flotufolastat(原18F-rhPSMA-7.3)在新诊断为高危前列腺癌且常规影像学阴性的男性中的临床应用。主要终点是临床抢先期率及其对后续治疗的影响。方法:纳入113例treatment-naïve符合NCCN高危标准的男性;110例患者行PSMA PET/CT检查,并应用18f - flofolastat。在影像学检查之前,所有患者的常规分期均为阴性,由骨扫描和CT或MRI确定。注射8mci±20% 18f - flofolastat后50-70分钟成像。结果由经过PSMA成像培训的委员会认证核医学医师进行解释。结果:18F-flotufolastat在110例患者中发现了36例前列腺外病变(32.7%)。其中,36例中有15例(41.7%)有孤立的区域淋巴结(N1)受累,而36例中有21例(58.3%)表现为远处转移性(M1)疾病。在被抢镜的患者中,36例患者中有34例(94.4%)改变了治疗方案。最常见的强化治疗包括添加雄激素受体抑制剂和扩大放疗范围(50.0%)。此外,34.3%的患者接受了化疗、雄激素受体抑制剂和放疗。少数患者(8.6%)将根治性前列腺切除术作为多模式治疗的第一步。结论:PSMA PET/CT加18f - flofolastat导致近三分之一的高危前列腺癌男性患者临床显影,常规影像学阴性,导致大多数患者治疗发生显著变化。这些发现支持将psma靶向成像整合到高危前列腺癌患者的初始分期途径中。
{"title":"Utility of <sup>18</sup>F-Flotufolastat PET/CT Imaging in High-Risk Prostate Cancer in a Real-World Setting.","authors":"Zachariah Taylor, Kayla Meyer, Nachum Stollman, Cheryl Zinar, Laurence Belkoff, Ilia Zeltser","doi":"10.1097/UPJ.0000000000000971","DOIUrl":"https://doi.org/10.1097/UPJ.0000000000000971","url":null,"abstract":"<p><strong>Introduction: </strong>This investigator-initiated, prospective low-intervention phase 3 study evaluated the clinical utility of PSMA PET/CT imaging with <sup>18</sup>F-flotufolastat (formerly <sup>18</sup>F-rhPSMA-7.3) in men with newly diagnosed high-risk prostate cancer and negative conventional imaging. The primary endpoint was the rate of clinical upstaging and its effect on subsequent management.</p><p><strong>Methods: </strong>A total of 113 treatment-naïve men meeting NCCN high-risk criteria were enrolled; 110 underwent PSMA PET/CT with <sup>18</sup>F-flotufolastat. Prior to imaging, all patients had negative conventional staging, as determined by bone scan and CT or MRI. Imaging was performed 50-70 minutes post-injection of 8 mCi ± 20% <sup>18</sup>F-flotufolastat. Results were interpreted by board-certified nuclear medicine physicians trained in PSMA imaging.</p><p><strong>Results: </strong><sup>18</sup>F-flotufolastat identified extraprostatic disease in 36 of 110 patients (32.7%). Among these, 15 of 36 (41.7%) had isolated regional lymph node (N1) involvement, while 21 of 36 (58.3%) demonstrated distant metastatic (M1) disease. Of the patients who were upstaged, 34 of 36 patients (94.4%) had a change in their treatment plan. The most common treatment intensification included the addition of an androgen receptor inhibitor and expanded radiotherapy fields (50.0%). Further, 34.3% received upfront chemotherapy alongside an androgen receptor inhibitor and radiation. A minority (8.6%) proceeded with radical prostatectomy as a first step of a multimodality approach.</p><p><strong>Conclusion: </strong>PSMA PET/CT with <sup>18</sup>F-flotufolastat led to clinical upstaging in nearly one-third of men with high-risk prostate cancer and negative conventional imaging, resulting in significant treatment change in most patients. These findings support the integration of PSMA-targeted imaging into initial staging pathways for men with high-risk prostate cancer.</p>","PeriodicalId":45220,"journal":{"name":"Urology Practice","volume":" ","pages":"101097UPJ0000000000000971"},"PeriodicalIF":1.7,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145953303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial Commentary. 编辑评论。
IF 1.7 Q4 UROLOGY & NEPHROLOGY Pub Date : 2026-01-12 DOI: 10.1097/UPJ.0000000000000960
Samuel H Eaton
{"title":"Editorial Commentary.","authors":"Samuel H Eaton","doi":"10.1097/UPJ.0000000000000960","DOIUrl":"10.1097/UPJ.0000000000000960","url":null,"abstract":"","PeriodicalId":45220,"journal":{"name":"Urology Practice","volume":" ","pages":"101097UPJ0000000000000960"},"PeriodicalIF":1.7,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145953116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Urology Practice
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1